



Journal of Hospital Pharmacy
An Official Publication of Bureau for Health & Education Status Upliftment
(Constitutionally Entitled as Health-Education, Bureau)

**Drug Information of Olanzapine/Samidorphane and their
Effectiveness in Schizophrenia: A Clinical Review**

Dhwanil Nileshkumar Mithaiwala^{1}, Sachi Anilkumar Chavda¹, Darshita Sureshbhai Raval²,
Neel Sureshbhai Raval¹, Vatsal Dineshbhai Patel¹*

¹Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat

²Parul Institute of Nursing, Parul University, Vadodara, Gujarat

AUTHOR & CORRESPONDING AUTHOR:


Dhwanil Nileshkumar Mithaiwala, Doctor of Pharmacy, Department of Pharmacy Practice,
Parul University, Vadodara, Gujarat, India.

Email Id: serviceheb@gmail.com

ABSTRACT:

Schizophrenia is the leading cause of disability in persons of all ages. In India, around 4 million cases are recorded each year. According to a comprehensive global survey, schizophrenia accounts for 1.1 percent of total disability-adjusted life years and 2.8 percent of disability years lived worldwide. LYBALVI (olanzapine/samidorphane) is an oral antipsychotic and opioid antagonist that, when taken orally, reduces weight gain induced by antipsychotic monotherapy. Recent studies have also demonstrated the efficacy of LYBALVI and claimed that it is safe for schizophrenia. Our study focuses on the medication LYBALVI (olanzapine/samidorphane) and its clinical significance in schizophrenia.

Keywords: anti-psychotics, weight gain, psychiatric illness, opioids, pharmacokinetics

Access this Article Online	Quick Response Code: 
Website: http://www.journalofhospitalpharmacy.in	
Received on 22/03/2022	
Accepted on 26/03/2022 © HEB All rights reserved	